WO1996029045A1 - Compostions antipelliculaires - Google Patents
Compostions antipelliculaires Download PDFInfo
- Publication number
- WO1996029045A1 WO1996029045A1 PCT/US1996/003988 US9603988W WO9629045A1 WO 1996029045 A1 WO1996029045 A1 WO 1996029045A1 US 9603988 W US9603988 W US 9603988W WO 9629045 A1 WO9629045 A1 WO 9629045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- treatment
- dandruff
- composition
- antifungal agent
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 25
- 208000001840 Dandruff Diseases 0.000 title claims description 18
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 19
- 239000003429 antifungal agent Substances 0.000 claims abstract description 19
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 15
- 239000002254 cytotoxic agent Substances 0.000 claims abstract description 15
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 15
- 210000004761 scalp Anatomy 0.000 claims abstract description 12
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims abstract description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 150000002460 imidazoles Chemical class 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002206 bifonazole Drugs 0.000 claims description 2
- 229960004022 clotrimazole Drugs 0.000 claims description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003245 coal Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960003483 oxiconazole Drugs 0.000 claims description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 claims description 2
- 229960005265 selenium sulfide Drugs 0.000 claims description 2
- 239000011269 tar Substances 0.000 claims description 2
- 229940026191 topical antipsoriatics tars Drugs 0.000 claims description 2
- 229940043810 zinc pyrithione Drugs 0.000 claims description 2
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 claims 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims 1
- 229960003913 econazole Drugs 0.000 claims 1
- 229960004849 isoconazole Drugs 0.000 claims 1
- 229960004130 itraconazole Drugs 0.000 claims 1
- 229960004125 ketoconazole Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011280 coal tar Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/23—Sulfur; Selenium; Tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Definitions
- the invention relates to pharmaceutical compositions for use in the treatment of seborrheic dermatitis of the scalp.
- Dandruff seborrheic dermatitis of the scalp, is a common disease involving 3-5% of the population. Dandruff is, in many cases, the precursor of alopecia (baldness) and constitutes a chronic and almost intractable cosmetical and social inconvenience. The pathophysiology of the disease remains unknown, although it is known to involve a hyperproliferat ⁇ ive state of the skin, a limited inflammatory process, and a secondary microbial colonization by the lipophilic yeast Pityrosporum, which is abundant and significantly ovcrpopulated on the scalp of seborrheic patients. Dandruff is a chronic and almost incurable disease. Available treatments result only in short term effects with an eventual recurrence of the disease.
- a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
- a traditional treatment of dandruff included administration onto the scalp of either a cytotoxic agent or an antifungal agent.
- the present invention provides by a first of its aspects a composition, e g in the form of a hair shampoo, for the treatment of dandruff or of symptoms associated therewith, comprising in combination an effective amount of at least one cytotoxic agent and an effective amount of at least one antifungal agent, together with a carrier, a diluent or an excipient
- effective amount means to denote an amount of an agent effective in achieving a therapeutic result in the treatment of dandruff, such as alleviation of itching, a decrease in the amount of scales, a reduction in the rate of hair loss, a reduction in scalp redness, etc.
- cytotoxic agent as used herein means to denote an agent which inhibits proliferation of keratinocytes skin cells.
- antifungal agent will be used to denote an agent which is specifically active in inhibiting growth of fungus and the fungus' ability to colonize the skin, which includes, inter alia, agents which are destructive to fungi, or active in suppressing growth of fungus or affect their ability to reproduce
- cytotoxic agent refers to agents which arc known in the art primarily by having cytotoxic activity
- antifungal agent refers to agents which are known in the art primarily by their antifungal activity
- cytotoxic agents useful in accordance with the invention are coal tars, selenium sulfide, zinc pyrithione or the like.
- the preferred cytoxic agent is coal tar, typically included in the composition in concentration of 1-5%.
- antifungal agents useful in accordance with the invention include imidazoles, ciclopiroxolamines and metronidazolcs.
- the imidazoles which arc preferred in accordance with the invention, include ketoconozole, bifonazole, itraconazolc, cconazole, clotrimazole, miconazole, oxiconazole, isoconazolc and the like. From the imidazoles, ketoconozole is particularly preferred.
- the antifungal agent is included in the composition in a concentration of 0.5-5%
- the present invention further provides the use of said cytotoxic agent in combination with said antifungal agent for the preparation of a composition, e.g. a medical hair shampoo, for the treatment of dandruff.
- a composition e.g. a medical hair shampoo
- a further aspect of the invention is concerned with the treatment of individuals suffering from dandruff by combined application to the scalp of such individuals of said cytotoxic agent and of said antifungal agent.
- the individuals may be treated by the use of a single composition, e.g. in the form of a hair shampoo, comprising both agents.
- the individuals may be treated by a combination of two different compositions, one comprising said cytotoxic agent and the other said antifungal agent. The above described combination may be applied 3-4 times during the first week from the start of the treatment, and 1-2 times a week, thereafter.
- the present invention also pertains to a package comprising at least two compositions, one comprising said antifungal agent and the other said cytotoxic agent, optionally with instructions for use in said method.
- Example 1 A group of six patients (ages 17-38) with a severe case of dandruff were on a regular bi-weekly anti seborrheic treatment prior to the onset of the experiment. During the experiment they were treated with a combination of the following two compositions: a. a composition comprising 1.8% coal tar. b. a solution comprising 2% kctoconazole.
- the patients were instructed to apply the two compositions, one after the other, in an amount sufficient to cover the entire scalp.
- the patients were instructed to apply the compositions on days 1 , 3, 6 and 9.
- the patients' conditions were examined after 14 or 30 days following the onset of treatment.
- the patients' conditions were evaluated by the following criteria: (i) scaling - existence of scales on the scalp, typically at the temporal area; (ii) itching - based on the patient's subjective feeling; (iii) severity - overall assessment of the dandruff disease situation, taking into account the skin redness as an indication of inflammatorv conditions. - D -
- Example 1 A group of three patients who had no record of treatment for dandruff prior to the onset of the experiment, was given the same treatment as in Example 1. The patients' condition was as severe as in Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
On traite l'eczéma séborrhéique du cuir chevelu au moyen d'une combinaison d'un agent cytotoxique et d'un agent antifongique.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU55261/96A AU5526196A (en) | 1995-03-21 | 1996-03-20 | Compositions for the treatment of dandruff |
| US08/913,650 US6075017A (en) | 1995-03-21 | 1996-03-20 | Compositions for the treatment of dandruff |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL113057 | 1995-03-21 | ||
| IL11305795A IL113057A (en) | 1995-03-21 | 1995-03-21 | Compositions for the treatment of dandruff |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1996029045A1 true WO1996029045A1 (fr) | 1996-09-26 |
Family
ID=11067236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/003988 WO1996029045A1 (fr) | 1995-03-21 | 1996-03-20 | Compostions antipelliculaires |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5526196A (fr) |
| IL (1) | IL113057A (fr) |
| WO (1) | WO1996029045A1 (fr) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997029733A1 (fr) * | 1996-02-16 | 1997-08-21 | Janssen Pharmaceutica N.V. | Compositions contenant un antifongique et un compose soufre |
| WO1999030675A1 (fr) * | 1997-12-18 | 1999-06-24 | Johnson & Johnson Consumer Companies, Inc. | Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu |
| WO2000006144A1 (fr) * | 1998-07-27 | 2000-02-10 | Howard Murad | Compositions pharmaceutiques et methodes de lutte contre des affections du cuir chevelu |
| WO2001012140A1 (fr) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Preparations cosmetiques |
| US6469033B1 (en) | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
| US6916479B2 (en) | 1997-04-14 | 2005-07-12 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a phospholipid |
| US7018656B2 (en) | 1996-09-27 | 2006-03-28 | Aventis Pharma Deutschland Gmbh | Antimycotic gel with high active substance release |
| RU2311904C1 (ru) * | 2006-02-09 | 2007-12-10 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) | Способ лечения микроспории кошек |
| US7981909B2 (en) | 1996-09-27 | 2011-07-19 | Medicis Pharmaceutical Corporation | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
| US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
| US4518789A (en) * | 1982-06-30 | 1985-05-21 | Yu Ruey J | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use |
-
1995
- 1995-03-21 IL IL11305795A patent/IL113057A/en not_active IP Right Cessation
-
1996
- 1996-03-20 AU AU55261/96A patent/AU5526196A/en not_active Abandoned
- 1996-03-20 WO PCT/US1996/003988 patent/WO1996029045A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4294852A (en) * | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
| US4491588A (en) * | 1982-03-31 | 1985-01-01 | University Of Tennessee Research Corporation | Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics |
| US4518789A (en) * | 1982-06-30 | 1985-05-21 | Yu Ruey J | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997029733A1 (fr) * | 1996-02-16 | 1997-08-21 | Janssen Pharmaceutica N.V. | Compositions contenant un antifongique et un compose soufre |
| US7018656B2 (en) | 1996-09-27 | 2006-03-28 | Aventis Pharma Deutschland Gmbh | Antimycotic gel with high active substance release |
| US6469033B1 (en) | 1996-09-27 | 2002-10-22 | Aventis Pharma Deutschland Gmbh | Use of 1-hydroxy-2-pyridones for the treatment of skin diseases |
| US7026337B2 (en) | 1996-09-27 | 2006-04-11 | Aventis Pharma Deutschland Gmbh | Antimycotic gel having high active compound release |
| US7981909B2 (en) | 1996-09-27 | 2011-07-19 | Medicis Pharmaceutical Corporation | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
| US6916479B2 (en) | 1997-04-14 | 2005-07-12 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a phospholipid |
| US6099870A (en) * | 1997-12-18 | 2000-08-08 | Johnson & Johnson Consumer Companies, Inc. | Methods for improving the health of hair and scalp |
| WO1999030675A1 (fr) * | 1997-12-18 | 1999-06-24 | Johnson & Johnson Consumer Companies, Inc. | Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu |
| WO2000006144A1 (fr) * | 1998-07-27 | 2000-02-10 | Howard Murad | Compositions pharmaceutiques et methodes de lutte contre des affections du cuir chevelu |
| WO2001012140A1 (fr) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Preparations cosmetiques |
| DE19938404A1 (de) * | 1999-08-13 | 2001-02-22 | Clariant Gmbh | Kosmetische Zubereitungen |
| US6663875B2 (en) | 1999-08-13 | 2003-12-16 | Clariant Gmbh | Hair preparation for the treatment of dandruff |
| RU2311904C1 (ru) * | 2006-02-09 | 2007-12-10 | Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Сибирского отделения Россельхозакадемии (ГНУ ИЭВСиДВ СО РАСХН) | Способ лечения микроспории кошек |
Also Published As
| Publication number | Publication date |
|---|---|
| IL113057A0 (en) | 1995-06-29 |
| IL113057A (en) | 1999-01-26 |
| AU5526196A (en) | 1996-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5951989A (en) | Method for the treatment of dry skin | |
| Faergemann | Management of seborrheic dermatitis and pityriasis versicolor | |
| EP0961609B1 (fr) | Methodes permettant d'ameliorer l'etat du cheveu et du cuir chevelu | |
| EP0500745B1 (fr) | Compositions de metaux-peptides et procede cosmetique pour la stimulation de la croissance des cheveux | |
| EP0737471A2 (fr) | Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue | |
| EP0673643B1 (fr) | Composition cosmétique contenant en association une superoxyde dismutase et une porphyrine | |
| WO1996029045A1 (fr) | Compostions antipelliculaires | |
| Abílio et al. | Effects of melatonin on orofacial movements in rats | |
| US6673842B2 (en) | Method of treating onychomycosis | |
| US6075017A (en) | Compositions for the treatment of dandruff | |
| US6986896B2 (en) | Method of treating fungal conditions of the skin | |
| CA2322149A1 (fr) | Utilisation d'un compose inhibant l'activite d'un canal sodium ou d'un canal calcium dans une composition a usage topique | |
| FR2769838A1 (fr) | Utilisation de derives d'azole pour la preparation d'une composition dermatologique ou cosmetologique | |
| Ive | An overview of experience with ketoconazole shampoo | |
| Lee et al. | Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea | |
| US20090197954A1 (en) | Linoleic acid preparations for the topical treatment of male and female pattern androgenetic alopecia, age-related alopecia, and keratosis pilaris | |
| Nakagawa et al. | Comparative study of FK506 (tacrolimus) ointment vs. alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions) | |
| KR20220071218A (ko) | 비듬에 대응하기 위한 시클로피록스올라민 및 피록톤 올라민의 조합물 | |
| RU2832017C1 (ru) | Комбинация циклопироксоламина и пироктоноламина для борьбы с перхотью | |
| JPH0112725B2 (fr) | ||
| WO2023217936A1 (fr) | Nouvelle utilisation d'un mélange de sucres comprenant du psicose, du mannose, du fructose et du glucose | |
| McGavack et al. | A clinical investigation of beta-morpholino-ethyl benzhydryl ether hydrochloride (linadryl) as an antihistamine agent | |
| EP4011360A1 (fr) | Complexe cosmétique pour l'hydratation de la peau, utilisation de ce complexe cosmétique, composition cosmétique et méthode d'hydratation de la peau | |
| Metze et al. | Hydroxyethylstarch (HES)-associated pruritus as a result of long-term storage in cutaneous nerves | |
| KR20090039458A (ko) | 편백 오일를 함유한 비듬균 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 08913650 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |